読み込み中
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
前日終値
$0.9796
+$0.0696 · +7.65%
日中の時刻はETです。市場データは遅延する場合があります。
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
日中レンジ
現在 $0.9796
52週レンジ
現在 $0.9796
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
40
割高
センチメント
31
弱気
リスク
66
高リスク
モメンタム
22
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
日中レンジ
現在 $0.9796
52週レンジ
現在 $0.9796
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | 188.5万 USD | 1994.3万 USD | 1640.1万 USD | — |
| 売上原価 | 163.4万 USD | 181.4万 USD | 176.4万 USD | 251万 USD | — |
| 粗利益 | −163.4万 USD | 7.1万 USD | 1817.9万 USD | 1389.1万 USD | — |
| 研究開発 | 4483万 USD | 5643.4万 USD | 4177.6万 USD | 5376.1万 USD | 3526.9万 USD |
| 販売・一般管理 | 1584.7万 USD | 1904.5万 USD | 1867万 USD | 2150.1万 USD | 1481.8万 USD |
| 営業費用 | 5904.3万 USD | 7366.5万 USD | 5868.2万 USD | 6994.7万 USD | 5008.7万 USD |
| 受取利息 | 310.8万 USD | 667.3万 USD | 741.6万 USD | 190.8万 USD | 10.4万 USD |
| 支払利息 | 527.4万 USD | 465.6万 USD | 313.9万 USD | — | — |
| 減価償却費と償却費 | 163.4万 USD | 181.4万 USD | 176.4万 USD | 110.4万 USD | 21.6万 USD |
| 営業利益 | −6067.7万 USD | −7359.4万 USD | −4050.3万 USD | −5605.6万 USD | −5008.7万 USD |
| 純利益 | −6082.2万 USD | −7051.5万 USD | −3736.8万 USD | −5381万 USD | −4998.3万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$6.50
上昇余地（563.54%）AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
